

General Assembly

Raised Bill No. 1421

January Session, 2025

LCO No. 5498



Referred to Committee on HUMAN SERVICES

Introduced by: (HS)

## AN ACT CONCERNING MEDICAID COVERAGE FOR OBESITY TREATMENT.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 Section 1. (NEW) (*Effective from passage*) (a) Not later than thirty days
- 2 after the effective date of this section, the Commissioner of Social
- 3 Services shall petition the Secretary of the Department of Health and
- 4 Human Services pursuant to 28 USC 1498, as amended from time to
- 5 time, to authorize generic, lower cost forms of glucagon-like peptide
- 6 (GLP-1) prescription drugs approved by the federal Food and Drug
- 7 Administration to treat obesity or diabetes.
- 8 (b) Upon approval of such petition, the commissioner shall enter into
- 9 a contract with any manufacturer of generic forms of such drugs
- approved by the federal Food and Drug Administration to supply such
- 11 drugs to the state for use by HUSKY Health program members. The
- 12 commissioner may enter into a consortium with officials in other states
- in contracting with such manufacturer for such drugs.
- 14 (c) The commissioner shall develop a strategic plan to maximize
- 15 access to and minimize the cost of such drugs and, not later than

LCO No. 5498 1 of 3

- 16 December 31, 2025, submit a report, in accordance with the provisions
- of section 11-4a of the general statutes, on the plan to the joint standing
- 18 committee of the General Assembly having cognizance of matters
- 19 relating to human services and to the advisory committee established
- 20 pursuant to section 2 of this act.
- 21 Sec. 2. (Effective from passage) (a) There is established an advisory
- 22 committee to (1) study ways to maximize access to cost-effective
- 23 prescription drugs approved by the federal Food and Drug
- 24 Administration for the treatment of obesity, and (2) make
- 25 recommendations to the Commissioner of Social Services.
- 26 (b) The committee shall consist of the following members:
- 27 (1) Two patient advocates appointed by the chairperson of the
- 28 Council on Medical Assistance Program Oversight, established
- 29 pursuant to section 17b-28 of the general statutes;
- 30 (2) Two pharmacists enrolled as Medicaid providers, appointed by
- 31 the Commissioner of Social Services; and
- 32 (3) Two medical professionals, including at least one doctor certified
- 33 by the American Board of Obesity Medicine, appointed by the Senate
- 34 and House chairpersons of the joint standing committee of the General
- 35 Assembly having cognizance of matters relating to human services.
- 36 (c) The committee shall convene not later than thirty days after the
- 37 effective date of this section and choose a chairperson. The committee
- 38 shall meet at least bimonthly.
- 39 (d) The committee shall review the strategic plan developed by the
- 40 Commissioner of Social Services pursuant to section 1 of this act and
- 41 shall make recommendations to the commissioner on implementation
- of the plan and the results of its study not later than January 31, 2026.
- 43 The committee shall terminate upon submission of its recommendations
- 44 to the commissioner or January 31, 2026, whichever is later.

LCO No. 5498 **2** of 3

This act shall take effect as follows and shall amend the following		
sections:		
Section 1	from passage	New section
Sec. 2	from passage	New section

## Statement of Purpose:

To allow the state to pursue cost-effective alternatives to brand name drugs prescribed to HUSKY Health program members for obesity treatment.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]

LCO No. 5498 3 of 3